Topics

Gilead, Galapagos announce 52-week results of filgotinib in FINCH 1, FINCH 3 studies in rheumatoid arthritis

07:55 EDT 11 Oct 2019 | Pharmaceutical Business Review

“We are encouraged by the durability of both the efficacy and safety profiles of filgotinib seen in these studies,” said John Sundy, MD, PhD, Senior Vice President, Inflammation

The post Gilead, Galapagos announce 52-week results of filgotinib in FINCH 1, FINCH 3 studies in rheumatoid arthritis appeared first on Pharmaceutical Business review.

Original Article: Gilead, Galapagos announce 52-week results of filgotinib in FINCH 1, FINCH 3 studies in rheumatoid arthritis

NEXT ARTICLE

More From BioPortfolio on "Gilead, Galapagos announce 52-week results of filgotinib in FINCH 1, FINCH 3 studies in rheumatoid arthritis"

Quick Search